Skip to main content
. 2019 Sep 4;18(5):4467–4480. doi: 10.3892/ol.2019.10807

Figure 2.

Figure 2.

Comparison of ex-miR-21 and ex-miR-92a levels between patients with GC and healthy volunteers. (A) Comparison of ex-miR-21 levels between patients with GC (n=129) and healthy volunteers (n=20). (B) Comparison of ex-miR-92a levels between patients with GC (n=129) and healthy volunteers (n=20). ex-, exosome-encapsulated; GC, gastric cancer; miR, microRNA.